A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

ClinicalTrials.gov ID: NCT06442436

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06442436. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study to Evaluate the Pharmacokinetics of Nemtabrutinib in Participants With Moderate Hepatic Impairment

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemtabrutinib (MK-1026) following a single oral dose of nemtabrutinib in participants with moderate hepatic impairment to that of healthy matched control participants and to evaluate the safety and tolerability of nemtabrutinib.

Study identification

NCT ID: NCT06442436
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Enrollment: 24 participants

Conditions and interventions

Conditions

Hepatic Impairment (HI)

Interventions

Nemtabrutinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 24, 2024 (Actual)
Primary completion: Aug 13, 2026 (Actual)
Completion: Aug 13, 2026 (Actual)
Last update posted: Sep 2, 2026

2024 – 2026

United States locations

U.S. sites: 3
U.S. states: 2
U.S. cities: 3

Facility	City	State	ZIP	Site status
Clinical Pharmacology of Miami ( Site 0003)	Miami	Florida	33172	—
Orlando Clinical Research Center ( Site 0001)	Orlando	Florida	32809	—
Texas Liver Institute ( Site 0002)	San Antonio	Texas	78215	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06442436, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 2, 2026 · Synced Nov 15, 2026